"Ongoing Adderall Shortage Worsens Struggles for ADHD Patients"
An ongoing shortage of Adderall and similar medications used to treat ADHD in the US has led to a significant decrease in prescription fill rates, affecting about 1 in 10 people with ADHD. Data from Truveta shows a decline in prescription fill rates, particularly for adults, following the shortage announcement by the FDA in October 2022. The shortage has created challenges for individuals in managing their symptoms, impacting work, relationships, and personal safety. Experts warn that inconsistent access to treatment can be disruptive and dangerous for people with ADHD, emphasizing the need to address the shortage to prevent adverse health outcomes.